📊 ACRS Key Takeaways
Is Aclaris Therapeutics, Inc. (ACRS) a Good Investment?
Aclaris is a development-stage biopharmaceutical company with severely deteriorating fundamentals: revenue collapsed 58% YoY to just $2M while operating losses exceed $22M annually. Despite a solid balance sheet (low debt, $28.7M cash), the company is burning ~$18M in operating cash annually, providing less than 2 years of runway. Without evidence of near-term revenue inflection or successful pipeline advancement, the deteriorating commercial performance and mounting losses present significant risk.
Aclaris Therapeutics shows very weak fundamentals, with revenue down 58.2% year over year and extremely negative operating and net margins, indicating the business is far from self-sustaining. While the balance sheet is not heavily levered and liquidity ratios look solid on paper, the combination of heavy operating losses and roughly $47M of annual free cash outflow versus only about $20M of cash creates substantial funding risk and weak growth quality.
Aclaris Therapeutics, Inc. Key Strengths (ACRS)
- Strong liquidity position with 4.03x current ratio and $28.7M cash reserves
- Conservative balance sheet with minimal leverage (0.07x debt-to-equity ratio)
- Improved loss per share metrics (69% YoY improvement, though still negative)
- Low financial leverage with debt-to-equity of 0.10x and limited long-term debt
- Positive gross profit and a 41.4% gross margin indicate some residual economic value in revenue streams
- Current and quick ratios of 3.36x suggest near-term liabilities are manageable
ACRS Stock Risks: Aclaris Therapeutics, Inc. Investment Risks
- Dramatic 58% YoY revenue decline indicates failed commercialization or lost revenue sources
- Severe cash burn of $18.1M in operating cash flow with only ~1.6 years of runway remaining
- Extreme unprofitability with net margins of -993% and operating losses of -$22.2M on minimal revenue base
- Suspicious 162% gross margin suggests non-core revenue sources rather than sustainable product sales
- No evidence of profitable path or near-term revenue stabilization
- Revenue contraction of 58.2% YoY suggests weak commercial traction or unstable revenue sources
- Operating margin of -975.9% and net margin of -829.6% reflect an unsustainably unprofitable cost structure
- Negative free cash flow of $47.22M against $19.96M of cash implies likely external financing needs if burn is not reduced
Key Metrics to Watch
- Quarterly revenue trajectory and stabilization of commercial products
- Monthly cash burn rate and updated cash runway projections
- Pipeline advancement milestones and potential FDA approvals or commercial launches
- Operating cash flow improvement and path to cash flow breakeven
- Quarterly cash burn relative to cash and equivalents
- Revenue stabilization and operating loss reduction
Aclaris Therapeutics, Inc. (ACRS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.03x current ratio provides a solid financial cushion.
ACRS Profit Margin, ROE & Profitability Analysis
ACRS vs Healthcare Sector: How Aclaris Therapeutics, Inc. Compares
How Aclaris Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aclaris Therapeutics, Inc. Stock Overvalued? ACRS Valuation Analysis 2026
Based on fundamental analysis, Aclaris Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aclaris Therapeutics, Inc. Balance Sheet: ACRS Debt, Cash & Liquidity
ACRS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aclaris Therapeutics, Inc.'s revenue has grown significantly by 177% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.71 indicates the company is currently unprofitable.
ACRS Revenue Growth, EPS Growth & YoY Performance
ACRS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.5M | -$15.1M | $-0.12 |
| Q3 2025 | $3.3M | -$7.6M | $-0.11 |
| Q2 2025 | $1.8M | -$11.0M | $-0.13 |
| Q1 2025 | $1.5M | -$15.1M | $-0.12 |
| Q3 2024 | $4.3M | -$7.6M | $-0.11 |
| Q2 2024 | $1.9M | -$11.0M | $-0.15 |
| Q1 2024 | $2.4M | -$16.9M | $-0.24 |
| Q3 2023 | $9.3M | -$18.8M | $-0.30 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Aclaris Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ACRS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aclaris Therapeutics, Inc. (CIK: 0001557746)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Jun 8, 2026 | 4 | xslF345X06/form4-06082026_040605.xml | View → |
| Jun 8, 2026 | 4 | xslF345X06/form4-06082026_040612.xml | View → |
| Jun 8, 2026 | 4 | xslF345X06/form4-06082026_040603.xml | View → |
| Jun 8, 2026 | 4 | xslF345X06/form4-06082026_040610.xml | View → |
| Jun 8, 2026 | 4 | xslF345X06/form4-06082026_040607.xml | View → |
❓ Frequently Asked Questions about ACRS
What is the AI rating for ACRS?
Aclaris Therapeutics, Inc. (ACRS) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACRS's key strengths?
Claude: Strong liquidity position with 4.03x current ratio and $28.7M cash reserves. Conservative balance sheet with minimal leverage (0.07x debt-to-equity ratio). ChatGPT: Low financial leverage with debt-to-equity of 0.10x and limited long-term debt. Positive gross profit and a 41.4% gross margin indicate some residual economic value in revenue streams.
What are the risks of investing in ACRS?
Claude: Dramatic 58% YoY revenue decline indicates failed commercialization or lost revenue sources. Severe cash burn of $18.1M in operating cash flow with only ~1.6 years of runway remaining. ChatGPT: Revenue contraction of 58.2% YoY suggests weak commercial traction or unstable revenue sources. Operating margin of -975.9% and net margin of -829.6% reflect an unsustainably unprofitable cost structure.
What is ACRS's revenue and growth?
Aclaris Therapeutics, Inc. reported revenue of $2.0M.
Does ACRS pay dividends?
Aclaris Therapeutics, Inc. does not currently pay dividends.
Where can I find ACRS SEC filings?
Official SEC filings for Aclaris Therapeutics, Inc. (CIK: 0001557746) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACRS's EPS?
Aclaris Therapeutics, Inc. has a diluted EPS of $-0.15.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ACRS's fundamental grade?
Based on our AI fundamental analysis in June 2026, Aclaris Therapeutics, Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ACRS stock overvalued or undervalued?
Valuation metrics for ACRS: ROE of -13.8% (sector avg: 15%), net margin of -993.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ACRS's AI grade for 2026?
Our dual AI analysis gives Aclaris Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACRS's free cash flow?
Aclaris Therapeutics, Inc.'s operating cash flow is $-18.1M, with capital expenditures of $13.0K. FCF margin is -909.9%.
How does ACRS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -993.2% (avg: 12%), ROE -13.8% (avg: 15%), current ratio 4.03 (avg: 2).